Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 135
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03351062 | Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | ||
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | ||
| NCT03895788 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | ||
| NCT05561686 | Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer | ||
| NCT06190652 | Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. | ||
| NCT05079074 | Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer | ||
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | ||
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | ||
| NCT06734533 | Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . | ||
| NCT05356351 | An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer | ||
| NCT04030845 | Patient Report Outcome-Reconstruction and Oncoplastic Cohort | ||
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC | ||
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | ||
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | ||
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | ||
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | ||
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | ||
| NCT06486545 | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | ||
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | ||
| NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | ||
| NCT07098026 | Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer | ||
| NCT04407988 | Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer | ||
| NCT06033287 | Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. | ||
| NCT06543108 | Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer | ||
| NCT03286920 | Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer | ||
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | ||
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | ||
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | ||
| NCT05484375 | Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | ||
| NCT06011330 | Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer | ||
| NCT05980208 | A Real-world Study of Inetetamab for First-line Treatment of MBC | ||
| NCT05633914 | Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | ||
| NCT05211232 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | ||
| NCT05430906 | AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer | ||
| NCT07083687 | Lorlatinib in ROS1+ NSCLC With Brain Metastasis | ||
| NCT05942768 | Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer | ||
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | ||
| NCT02448966 | Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy | ||
| NCT06458673 | A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules | ||
| NCT06195228 | A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | ||
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT06557590 | 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors | ||
| NCT05351346 | Genotype-guided Treatment in DLBCL | ||
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | ||
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | ||
| NCT02891083 | Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer | ||
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | ||
| NCT05244499 | Evidence-based Leadership in Nurse Leaders-CH | ||
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | ||
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). |
